PedAM
Pediatric Disease Annotations & Medicines
| Disease | thrombocytopenia |
| Phenotype | C0272286|immune thrombocytopenia |
| Sentences | 6 |
| PubMedID- 23190430 | Romiplostim is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy[18]. |
| PubMedID- 25170628 | Background/aim: thrombopoietin receptor agonists (romiplostim and eltrombopag) have recently been licensed for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (itp) with an insufficient response to corticosteroids, immunoglobulins or splenectomy. |
| PubMedID- 23008717 | Consistent with these observations, recent studies demonstrated that thrombocytopenia in patients with primary chronic autoimmune thrombocytopenia is associated with a significantly higher long-term risk of infection [73]. |
| PubMedID- 24623263 | To determine predictive factors for neonatal thrombocytopenia in deliveries with immune thrombocytopenia (itp), we conducted a retrospective study at a tertiary hospital between 1997 and 2013. |
| PubMedID- 22687850 | Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (itp) while administering romiplostim. |
| PubMedID- 23292974 | Romiplostim, a thrombopoietin mimetic, is fda approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. |
Page: 1